Zobrazeno 1 - 10
of 284
pro vyhledávání: '"Jeffrey J Swigris"'
Publikováno v:
BMJ Open Respiratory Research, Vol 10, Iss 1 (2023)
Many patients with fibrosing interstitial lung disease (fILD) will need to use supplemental oxygen (O2) to maintain normoxia at some point in their illness. If it is not needed at the time of diagnosis, then if fILD progresses—or if a comorbid cond
Externí odkaz:
https://doaj.org/article/2b002efcf9534738b7a3f46a67514691
Publikováno v:
BMJ Open Respiratory Research, Vol 10, Iss 1 (2023)
Background Interstitial lung disease due to rheumatoid arthritis (RA-ILD) affects a substantial minority of patients with RA, inducing life-altering symptoms, impairing quality of life (QOL) and forcing patients to confront the potential for shortene
Externí odkaz:
https://doaj.org/article/b3cca9f732844bb4b6b5c033330d1e74
Autor:
Franck Rahaghi, John A Belperio, John Fitzgerald, Mridu Gulati, Robert Hallowell, Kristin B Highland, Tristan J Huie, Hyun J Kim, Martin Kolb, Joseph A Lasky, Brian D Southern, Jeffrey J Swigris, Joao A de Andrade
Publikováno v:
Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, Vol 15 (2021)
Purpose: Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF), which slows disease progression. Management of patients with IPF receiving nintedanib can be complicated by tolerability issues, comorbidities, and concomitant medi
Externí odkaz:
https://doaj.org/article/dca028738ba248b488b444b301cd91bc
Autor:
Kerri I. Aronson, Mangala Rajan, Janani Varadarajan, Tessy K. Paul, Jeffrey J. Swigris, Jamuna K. Krishnan, Robert J. Kaner, Fernando J. Martinez, Monika M. Safford, Laura C. Pinheiro
Publikováno v:
ERJ Open Research, Vol 10, Iss 4 (2024)
Rationale and objective Disease-specific health-related quality of life (HRQOL) instruments enable us to capture domains that are most relevant to specific patient populations and are useful when a more individualised approach to patient assessment i
Externí odkaz:
https://doaj.org/article/569a28d2189c441da7a1ea7ece7d9b89
Publikováno v:
Jornal Brasileiro de Pneumologia, Vol 37, Iss 1, Pp 100-109 (2011)
Em pacientes com miosite, é comum o comprometimento pulmonar, e a presença de anticorpos anti-aminoacil-RNAt sintetase (anti-ARS) é preditora da presença ou do desenvolvimento de doença pulmonar intersticial (DPI). Uma entidade clínica distinta
Externí odkaz:
https://doaj.org/article/339a945f217942acb570fa08d8892212
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Dyspnea impairs quality of life (QOL) in patients with fibrotic hypersensitivity pneumonitis (FHP). The Living with Pulmonary Fibrosis questionnaire (L-PF) assesses symptoms, their impacts and PF-related QOL in patients with any f
Externí odkaz:
https://doaj.org/article/5014256a048c4f8f8f5d9fbcfc7124a7
Autor:
Timothy M. Wilson, Joshua J. Solomon, Stephen M. Humphries, Jeffrey J. Swigris, Faduma Ahmed, Hong Wang, Erika Darrah, M. Kristen Demoruelle
Publikováno v:
The American Journal of the Medical Sciences. 365:480-487
Autor:
Erica Farrand, Jeffrey J. Swigris
Publikováno v:
Current Opinion in Pulmonary Medicine. 29:322-327
Publikováno v:
Journal of General Internal Medicine. 37:2541-2547
Dyspnea is a common and debilitating symptom that affects many different patient populations. Dyspnea measures should assess multiple domains.To evaluate the reliability, validity, and responsiveness of an ultra-brief, multi-dimensional dyspnea measu
Autor:
Anna L. Peljto, Rachel Z. Blumhagen, Avram D. Walts, Jonathan Cardwell, Julia Powers, Tamera J. Corte, Joanne L. Dickinson, Ian Glaspole, Yuben P. Moodley, Martina Koziar Vasakova, Elisabeth Bendstrup, Jesper R. Davidsen, Raphael Borie, Bruno Crestani, Philippe Dieude, Francesco Bonella, Ulrich Costabel, Gunnar Gudmundsson, Seamas C. Donnelly, Jim Egan, Michael T. Henry, Michael P. Keane, Marcus P. Kennedy, Cormac McCarthy, Aoife N. McElroy, Joshua A. Olaniyi, Katherine M. A. O’Reilly, Luca Richeldi, Paolo M. Leone, Venerino Poletti, Francesco Puppo, Sara Tomassetti, Valentina Luzzi, Nurdan Kokturk, Nesrin Mogulkoc, Christine A. Fiddler, Nikhil Hirani, R. Gisli Jenkins, Toby M. Maher, Philip L. Molyneaux, Helen Parfrey, Rebecca Braybrooke, Timothy S. Blackwell, Peter D. Jackson, Steven D. Nathan, Mary K. Porteous, Kevin K. Brown, Jason D. Christie, Harold R. Collard, Oliver Eickelberg, Elena E. Foster, Kevin F. Gibson, Marilyn Glassberg, Daniel J. Kass, Jonathan A. Kropski, David Lederer, Angela L. Linderholm, Jim Loyd, Susan K. Mathai, Sydney B. Montesi, Imre Noth, Justin M. Oldham, Amy J. Palmisciano, Cristina A. Reichner, Mauricio Rojas, Jesse Roman, Neil Schluger, Barry S. Shea, Jeffrey J. Swigris, Paul J. Wolters, Yingze Zhang, Cecilia M. A. Prele, Juan I. Enghelmayer, Maria Otaola, Christopher J. Ryerson, Mauricio Salinas, Martina Sterclova, Tewodros H. Gebremariam, Marjukka Myllärniemi, Roberto G. Carbone, Haruhiko Furusawa, Masaki Hirose, Yoshikazu Inoue, Yasunari Miyazaki, Ken Ohta, Shin Ohta, Tsukasa Okamoto, Dong Soon Kim, Annie Pardo, Moises Selman, Alvaro U. Aranda, Moo Suk Park, Jong Sun Park, Jin Woo Song, Maria Molina-Molina, Lurdes Planas-Cerezales, Gunilla Westergren-Thorsson, Albert V. Smith, Ani W. Manichaikul, John S. Kim, Stephen S. Rich, Elizabeth C. Oelsner, R. Graham Barr, Jerome I. Rotter, Josee Dupuis, George O’Connor, Ramachandran S. Vasan, Michael H. Cho, Edwin K. Silverman, Marvin I. Schwarz, Mark P. Steele, Joyce S. Lee, Ivana V. Yang, Tasha E. Fingerlin, David A. Schwartz
Rationale: Idiopathic pulmonary fibrosis is a rare, irreversible, and progressive disease of the lungs. Common genetic variants, in addition to non-genetic factors, have been consistently associated with IPF. Rare variants identified by candidate gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0670c24aedc8efa23979477ed15d39b
http://hdl.handle.net/10044/1/101620
http://hdl.handle.net/10044/1/101620